Articles tagged with Cervical Cancer
A study on cancer trends in Canada from 1971 to 2015 found an increase in breast and colorectal cancers among younger adults, particularly women aged 30-39. In contrast, cancer incidence has decreased in older age groups, with declines seen in cervical, lung, bladder, and prostate cancers across most age categories.
A new study published in The American Journal of Pathology suggests that medroxyprogesterone acetate (MPA) is effective in preventing the development of cervical cancer in mice with precancerous lesions. MPA also decreased existing precancerous lesions, offering a non-invasive approach to combat cervical cancer.
A study found that cervical cancer screening rates decline among women aged 45-65, particularly those with lower education, rural residency, or lack of insurance. The study highlights the need for increased awareness and access to screenings for vulnerable populations.
A new study found that mailed self-sampling kits for HPV testing increased cervical cancer screening by 50% in underserved women, with 88% of testers negative for the virus. However, only 70% of women who tested positive followed up for follow-up testing.
Researchers developed a non-invasive test to detect cervical pre-cancer by analyzing urine and vaginal samples collected by women themselves. The test, called S5, measures DNA methylation and has been shown to accurately identify high-risk women with an HPV positive test.
Researchers developed a new approach to detect bacteria and viruses associated with cancers. By sequencing genomic data from tumors, they can identify pathogens linked to diseases such as stomach cancer and cervical cancer. The method holds promise for developing new cancer vaccines in the future.
A school-based HPV vaccination program in British Columbia has significantly reduced cervical pre-cancer rates among women, with a 57% reduction found in those vaccinated as Grade 6 girls compared to unvaccinated women. Regular cervical screening is crucial in preventing cervical cancer from developing.
A new study presents promising results from the CheckMate 358 trial, a phase I/II investigational immune-therapy trial combining nivolumab and ipilimumab for recurrent and metastatic cervical cancer. The combination showed higher clinical benefit rates compared to single-agent treatments.
The closure of nearly 100 women's health clinics in the US was associated with fewer cervical cancer screenings, more advanced diagnoses, and increased mortality rates. States with clinic closures saw a 2% drop in screenings, particularly among uninsured women, Hispanic women, and young adults.
A new diagnostic approach detects high-risk HPV infection and precancerous markers, improving the ability to diagnose cervical cancer in HPV-positive women. The test has a sensitivity of 97.3% and negative predictive value of 93.8%, making it a promising tool for cervical cancer triage.
A new study has found that psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer. Patients who experienced stress-related disorders or stressful life events were 33% more likely to die from the disease compared to those who did not report stress.
A new microfluidic array catches and holds single cervical cells for faster screening, trapping them with microscopic electrodes and analyzing them using immunofluorescent staining. The device effectively trapped 98% of cells and held on to 92%, providing a promising tool for cervical cancer diagnosis.
A new study published in Papillomavirus Research found that one dose of HPV vaccine lowers the chance of having a pre-cancerous lesion detected at cervical screening in women vaccinated at a young age. The data supports the possibility that one dose may be sufficient for protection, simplifying vaccination and potentially benefiting co...
Researchers found that people shared informational tweets about cervical cancer prevention significantly more than personal-experience tweets. Organization senders were more likely to share content, regardless of type.
A meta-analysis of 60 million individuals in high-income countries found significant decreases in HPV infections, anogenital wart diagnoses, and precancerous cervical lesions (CIN2+) after girls-only HPV vaccination. The study supports the WHO's revised position on vaccinating multiple age cohorts of girls aged 9-14 years old.
Researchers found that HPV vaccination programs substantially reduced HPV infections by 83% among girls aged 13-19 and 66% among women aged 20-24. Precancerous cervical lesions also decreased by 51% among teens and 31% among women in their early twenties.
A new study reveals significant global disparities in cervical cancer rates among women living with HIV, particularly in South Africa and Latin America. The analysis shows that ICC rates are more than double in Latin America and 11 times higher in South Africa compared to European women.
Researchers propose evaluating genomic analyzes in cervical cytologies to detect endometrial cancer at an early stage. Molecular tests can refine diagnostic algorithms and benefit asymptomatic women with a high risk of cancer.
Recent falls in vaccination rates and uptake of other preventative programs, such as bowel and breast cancer screenings, indicate a fragmentation of public health arrangements. Visible public health leadership is needed to address these weaknesses and prevent further deterioration.
A study models the demand, benefit, and cost of implementing a 20-year strategy for radiotherapy to treat cervical cancer in low- and middle-income countries. The research estimates that 9.4 million women will require radiotherapy, generating $151.5 billion in economic benefits.
The partnership aims to increase HPV vaccine uptake, which causes over 33,000 cancers annually. UVA will launch a multipronged campaign to educate healthcare workers and the public on the importance of HPV vaccination.
Researchers at the University of Arizona have discovered a 'metabolic fingerprint' that distinguishes patients with cervical cancer from healthy women. The study identified three compounds that distinguish cervical cancer patients from healthy women, showing promise for future diagnostics, interventions or therapies.
A cost-effectiveness analysis of 12 cervical cancer screening strategies incorporates women's preferences to estimate quality of life and economic outcomes. The study aims to provide a comprehensive evaluation of different screening methods, considering their potential impact on health and finances.
Researchers from Dartmouth's Norris Cotton Cancer Center have introduced an inexpensive DNA-based testing protocol for HPV in Honduras. The study found that of 1,732 women screened, 28% were positive for a high-risk HPV type, and the most common HPV genotypes detected were different than those commonly found in the US.
Researchers at University of Manchester found urine testing to be just as effective as the cervical smear in detecting high-risk human papillomavirus (HPV) that causes cervical cancer. The study suggests a urine test could increase participation rates for cervical cancer screening among younger women.
A new study reports that cervical adenocarcinoma incidence rates are increasing in non-Hispanic whites, particularly among women aged 40-49 and 50-59. This trend underscores the need for intensified efforts to improve screening utilization and HPV vaccination.
A study found cervical cancer tumors without human papillomavirus (HPV) are rare but have a worse prognosis, diagnosed at advanced stages with higher metastasis rates.
A Danish register-based study found that women over 65 have a 25-30% higher mortality rate from cervical cancer than previously thought. This age group is not covered by the country's screening program, leading to potentially late diagnoses and reduced treatment options.
A study published in The BMJ found that routine HPV vaccination in Scotland led to a significant reduction in cervical disease among young women. Vaccinated women showed an 89% reduction in CIN grade 3 or worse, while unvaccinated women also experienced a decrease in disease, possibly due to herd protection.
A recent study found that adults at high risk of HIV infection have significantly lower rates of HPV vaccination, with only 3.39% fully vaccinated among those with high-risk behaviors. The lowest vaccination rates were seen in non-Hispanic black respondents and LGBTQ+ individuals.
Researchers analyzed cervical precancers over seven years and found a 21% decline in CIN2+ cases attributed to HPV16/18. The proportion of these cases declined among vaccinated women, suggesting the vaccine's effectiveness in preventing cervical disease.
A modelling study predicts that combining high uptake of HPV vaccine and high HPV-based cervical screening rates can prevent up to 13.4 million cases of cervical cancer within 50 years. Cervical cancer elimination is expected in most countries by the end of the century, with average rates falling to less than 4 cases per 100,000 women.
A study found that social stigmas surrounding HPV can make women anxious about their health and put them off cervical screening. The new HPV screening method aims to address these concerns by providing a more accurate diagnosis, reducing the risk of false positives, and improving patient confidence.
A recent increase in vocal-cord cancer diagnoses among young adults, mostly non-smokers, is attributed to human papilloma virus (HPV) infection. HPV-associated strains are found in all tested samples of vocal-cord cancer from patients under 30, greatly resembling recurrent respiratory papillomatosis.
A Japanese study found an increase in cervical cancer rates, with a rise in incidence despite improved treatment survival rates. Younger patients surprisingly showed less resistance to radiation therapy, while older individuals had better outcomes for localized cancers.
A multi-pronged effort will be launched to combat cervical cancer in Malawi, with a focus on early screening and same-day treatment of precancerous lesions using thermocoagulation. The project aims to increase the number of women screened and treated, and decrease loss to follow up.
A large pilot study confirms HPV screening is practical on a large scale and more sensitive than smear testing, detecting substantially more cervical lesions and cancer. The study's findings support extending screening intervals to at least five years without increasing the risk of potentially life-threatening disease.
After Japan's HPV vaccination suspension, researchers at Osaka University suggest ways to reduce cervical cancer risk and promote vaccination. They propose targeted immunization for older women, the nine-valent vaccine, and a behavioral economics approach to boost public acceptance.
A population health study from IUPUI and Regenstrief Institute identified socioeconomic and racial disparities in health behaviors and screening for cancer in 34 Indiana counties. Black residents have lower cancer incidence but higher mortality rates, while those with low income and education face poor access to healthcare.
A new AI algorithm has been developed to analyze digital images of the cervix and identify precancerous changes, outperforming human experts in accuracy. The approach has the potential to transform cervical cancer screening, especially in areas with limited resources.
Researchers at UVA Health System have made a breakthrough in understanding human papillomavirus (HPV) and its role in causing cancers. They discovered that the virus relies on a specific enzyme, USP46, to form tumors, making it a promising target for new therapies.
A new epigenetic-based cervical cancer test outperformed Pap smear and HPV tests, detecting 100% of invasive cancers in a large study. The test also predicted early cancer development up to five years in advance.
Researchers have discovered a higher risk of cervical cancer in women whose cervical cells test positive for certain high-risk human papillomavirus types but do not show any signs of cellular abnormalities. A total of 96 cases were found to develop pre-cancerous changes and 4 cervical cancers during the 9-year follow-up period.
Researchers found that self-sampling kits can improve cervical cancer detection among women not participating in screening programs. Studies showed that HPV tests based on PCR technology were just as accurate on self-samples as those taken by clinicians, but signal amplification-based tests were less effective.
A pilot study from Ohio State University found that mailing at-home HPV tests to hard-to-reach women resulted in an 80% return rate, with about a quarter testing positive for cancer-causing HPV. The study aims to explore the potential of at-home testing as a tool to increase screening rates among underserved communities.
Researchers have discovered that dasatinib sensitizes triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells. Additionally, a systematic review and meta-analysis found an increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy.
A portable device that can screen for cervical cancer using a smartphone has been developed by researchers at the University of Arizona. The device is estimated to be less than $3,000 and can analyze images automatically, recommend treatment, and identify potentially cancerous areas. Its affordability, portability, and ease of use make...
Cornelis Melief is recognized for his life's work in studying the interactions of the immune system with cancer, leading to the development of new therapeutic cancer vaccine strategies. His research has shown clinical effectiveness in treating patients with pre-malignant lesions caused by HPV type 16.
Researchers found that mailing self-collection kits to test for high-risk human papillomavirus infection detected high-risk HPV in all cases of women with high-grade, abnormal cervical precancerous growths. This approach has the potential to boost cervical cancer screening, especially among low-income women who are overdue for testing.
Researchers discovered that cancer-causing papillomaviruses diverged from their common ancestors half a million years ago, coinciding with the split between Neanderthals and modern humans. The viruses adapted to specific host ecosystems and then coevolved with primates for at least 40 million years.
A new modeling study suggests that older women who test negative for human papillomavirus (HPV) with a DNA test may be at low risk of cervical cancer and could safely stop screening. However, regular cytology screening up to age 75 can still prevent cancers and is recommended for countries using HPV testing.
A new study found that women with early-stage cervical cancer who underwent minimally invasive hysterectomy had a significantly higher risk of death compared to those who had open surgery. This was due to a 65% higher risk of mortality within four years after surgery.
Patients receiving minimally invasive radical hysterectomy for early-stage cervical cancer have an increased risk of death compared to those treated with open surgery. A long-term analysis of nationwide databases found a 9.1% risk of death in the minimally invasive group, significantly higher than the 5.3% risk in the open surgery group.
Two studies found that minimally invasive radical hysterectomy is associated with higher recurrence rates and worse overall survival for women with early-stage cervical cancer. The findings have already changed care at MD Anderson Cancer Center and could impact surgical management of all women with early-stage disease.
A new study reveals that HIV-infected Hispanics in the US are at a higher risk of developing HPV-related cancers than their non-Hispanic counterparts. The study found significant disparities in cancer incidence rates among Hispanic and non-Hispanic populations, highlighting the need for targeted HPV-vaccination and screening programs.
Researchers at Karolinska Institutet found that high-risk HPV-positive tumours had a significantly higher five-year relative survival rate of 74% compared to hrHPV-negative tumours at 54%. The presence of high-risk HPV was also associated with earlier detection and improved socioeconomic status.
To achieve an 80% HPV vaccination rate by 2026, 14.39 million more US adolescents will need to receive the vaccine, with a disproportionate burden among males, whites, and privately insured teens. The majority of those who haven't been vaccinated yet had opportunities to do so during wellness visits.
A phase II clinical trial found that a tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) and had a median survival of 17.5 months.
The HPV vaccine offers a promising approach to lowering rates of cervical cancer and HPV-related diseases worldwide, particularly in underserved populations. Research highlights disparities in cervical cancer screening among different demographic groups, emphasizing the need for targeted interventions.
A new Ontario clinical study shows adding PET imaging to CT scans can change treatment plans for women with locally advanced cervix cancer. The study found that patients who received PET scans were twice as likely to have a change in their treatment, leading to more extensive radiation therapy.